Phase 4 N=153 A Text Messaging Program for Smokers in Primary Care
Smoking Cessation
Primary: Quit Attempts — 26; 33; 29; 31 Participants — p=0.07
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=4,614 A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
Acute Coronary Syndromes
Primary: The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist…
Phase 2 N=13 DAW1033B2 in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 33; 20.4 events/hour of sleep — p=0.47
Phase 2 N=343 Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
Chronic Migraine or Episodic Migraine
Primary: Change From Baseline in Monthly Migraine Days to the Last 4 Weeks of the 12 Week Double-Blind Treatment Period — -2.45; -2.20; -2.19 days — p=0.66
Phase 3 N=51 A Long-term Safety Study of QMF149 in Japanese Participants With Asthma
Asthma
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 40; 0 Participants
N/A N=40 Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC)
Anxiety Disorders
Primary: Hamilton Anxiety Rating Scale — 5; 6 Participants
Phase 2 N=223 Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Percentage of Participants With Stringent Complete Response (sCR) — 32.0; 42.4 Percentage of participants
N/A N=350 Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures
Persistent Atrial Fibrillation
Primary: Freedom From Procedure-related Serious Adverse Events (SAEs) Within 7-10 Days of the Procedure — 92.7; 88.9 % of participants — p=0.2179
Phase 2 N=12 Effects of High Dose Calcitriol in Breast Cancer Patients
Breast Cancer
Primary: Mean Change in Bone Resorption: NTX (N-terminal Telopeptide) — NA nmol
Phase 1 N=14 A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
NSCLC · Gastric Cancer
Primary: Dose-Escalation Phase: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 1 Participants
N/A N=345 Bulking Agents for the Treatment of Stress Urinary Incontinence in Females
Stress Urinary Incontinence
Primary: Primary Effectiveness Endpoint — 107; 50 participants
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 4 N=50 Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
ST Segment Elevation Myocardial Infarction · Percutaneous Coronary Intervention
Primary: Platelet Reactivity Measured by VerifyNow PRU — 63; 214 P2Y12 reaction units (PRU) — p=<0.001
Phase 2 N=460 A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults
Obesity · Overweight
Primary: Percent Change From Baseline in Body Weight at 24 Weeks — -1.24; -2.04; -3.52; -4.37 Percent change — p=<0.0001
N/A N=376 Foley Catheter Versus Cervidil for Induction of Labor at Term
Labor Induction
Primary: Time Of Start Of Induction Of Labor To Delivery — 21.6; 26.6 hours